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TO THE EDITOR
Semaphorins are secreted and trans-
membrane proteins initially described
as guidance signalling molecules dur-
ing the embryonic development of the
nervous system (Bagnard et al., 1998).
In addition, their involvement in pro-
cesses controlling cardiac and skeletal
development (Behar et al., 1996), cell
migration (Delaire et al., 2001), induc-
tion of apoptosis (Tomizawa et al.,
2001), immunomodulation (Bismuth
and Boumsell, 2002), and tumor growth
and metastasis (Roche et al., 1996;
Christensen et al., 1998) is now well
documented. Sema 3F is a member of
the class III semaphorin family, origin-
ally isolated as a tumor suppressor of
small-cell lung carcinoma (Roche et al.,
1996; Sekido et al., 1996; Xiang et al.,
1996), and which receptors have been
identified among the neuropilin (NRP)
family (Chen et al., 1997; Kolodkin
et al., 1997). An antimetastatic function
for Sema 3F has been recently sug-
gested in melanoma. Thus, the implan-
tation of metastatic melanoma cells
transfected with Sema 3F into nude
mice resulted in a tumor that did not
metastasize (Bielenberg et al., 2004).
Here we further report that Sema 3F can
represent a powerful inhibitor of mela-
noma cell proliferation.
Because the expression of a neuro-
pilin receptor is a pre-requisite for the
generation of a Sema 3F-dependent
signal, we first examined whether
NRP1 and NRP2 mRNA were present
in cells isolated from the melanoma
cutaneous metastases of six patients.
Both mRNAs were detected in the
melanoma cells originating from each
patient, although with varying degree of
expression (Figure 1, upper and middle
panel). In addition, Sema 3F transcript
was also detected in all tested samples
(Figure 1, lower panel). Therefore
melanoma cells might be potential
targets for Sema 3F, as they present
the ability to express the low- or high-
affinity receptor for this semaphorin.
The functional effects of Sema 3F on
melanoma cells were explored using
the human melanoma cell lines
MM170 and A375. The hypothesis of
Sema 3F binding to melanoma cells
was investigated by semaphorin bind-
ing assays. Figure 2a clearly demon-
strated an efficient interaction of Sema
3F with MM170 and A375 cell lines.
The semaphorin might influence the
functional behavior of these cells. We
further investigated the molecular basis
of Sema 3F interaction on MM170 and
A375 melanoma cell lines. Because
NRP1 and NRP2 mRNA synthesis was
detected in both cell lines (data not
shown), the cell surface expression of
each receptor was analyzed by flow
cytometry (Figure 2b). The immuno-
fluorescence labeling revealed a low
expression level of NRP1 on A375 cells,
whereas a higher protein amount was
detected on MM170 cells (Figure 2b,
left panel). In contrast, although NRP2
staining was found positive on both cell
lines, a stronger level of expression was
constantly observed on A375 cells
when compared to MM170 (Figure 2b,
middle panel). Additional protein ex-
pression analysis also led to the detec-
tion of membrane-associated Sema 3F
on both cell lines (Figure 2b, right
panel). Importantly, Sema 3F was also
found in MM170 and A375 culture
medium by performing anti-Sema 3F
immunoblotting, confirming the ability
of the cells to secrete properly the
semaphorin (data not shown). Alto-
gether, these data strongly suggested
that, following secretion, Sema 3F
might regulate MM170 and A375 cel-
lular functions through its binding to
NRP receptors.
It has been demonstrated that over-
expression of Sema 3F in a mouse
fibrosarcoma cell line, or in ovarian
cancer cells, inhibited in vitro and in
vivo cell growth but did not affect the
growth of lung carcinoma cells (Tomi-
zawa et al., 2001; Xiang et al., 2002).
Similarly, a consequent downregulation
of breast cancer cell proliferation has
been observed in the presence of Sema
3F (Nasarre et al., 2003). We therefore
investigated the influence of Sema 3F
on the proliferative response of MM170
and A375 cell lines. The results from a
representative dose–response experi-
ment are shown in Figure 2c, and
demonstrated a dose-dependent inhibi-
tory effect of Sema 3F on MM170 and
A375 cell proliferation. Importantly, the
observed inhibition of proliferation did
not derived from Sema 3F-induced
apoptosis or cell cycle arrest (data not
shown). We further confirmed the
specificity of Sema 3F-mediated down-
regulation of cell growth by performing
similar experiments on cells transiently
expressing the semaphorin. A 33%
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Figure 1. Expression of NRP1, NRP2, and Sema
3F mRNA by human melanoma cutaneous cells.
Reverse transcription-PCR was performed on
mRNA isolated from melanoma tumor cells of six
patients (1–6). Positive (þ ) and negative ()
controls were realized simultaneously for each
amplified product using cDNA from the indicated
cells as template. Dev: human pluripotent neural
precursor cell line.
Abbreviations: NRP, neuropilin
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inhibition of proliferation was mea-
sured on Sema 3F-expressing MM170
cells (Figure 2d). Similarly, A375 cells
exhibited a 31% reduction of cell
growth and division when secreting
soluble Sema 3F. Thus, Sema 3F dis-
plays a potent antiproliferative effect on
both MM170 and A375 melanoma cell
lines.
In this study, we demonstrated that
the addition of exogenous soluble
semaphorin Sema 3F, or overexpression
of the endogenous molecule, efficiently
affects the mechanisms regulating
MM170 and A375 melanoma cell line
proliferation. These results are contra-
dictory with the one reported by Bie-
lenberg et al. (2004), who demonstrated
that the expression of Sema 3F by
melanoma tumor cells diminished their
capacity to adhere and migrate but did
not affect their proliferation. However,
since the amount of semaphorin se-
creted by the transfected cells was not
quantified in this study, the observed
discrepancy might be attributed to the
secretion of suboptimal concentrations
of semaphorin (below 10 nM, according
to our dose–response experiment, see
Figure 2c), for which a Sema 3F-
dependent inhibition of cell prolifera-
tion will be hardly detectable. Impor-
tantly, we established that the cells
isolated from the cutaneous metastases
of patients with melanoma possess the
transcription machinery required for a
Sema 3F-induced inhibition of cell
growth and division, as assessed by
the synthesis of Sema 3F, NRP1, and
NRP2 mRNA. Although the expression
and functions of these proteins have to
be confirmed on melanoma cells ob-
tained from patients, our data strongly
suggested that Sema 3F might represent
a potent inhibitor of melanoma cell
proliferation and could be used for
therapeutic goal.
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Figure 2. Binding of Sema 3F to melanoma cells inhibits their proliferation. (a) Soluble alkaline phosphatase (AP; control) or Sema 3F-AP recombinant protein
were prepared from transiently transfected COS7 cells and used at a final concentration of 100 nM. Binding assays were performed on MM170 or A375
melanoma cell lines using the indicated protein, and protein ligation was visualized by colorimetry after addition of an AP substrate. (b) Cell surface expression
of NRP1, NRP2, and Sema 3F on MM170 and A375 cell lines. The presence of membrane-associated NRP1, NRP2, or Sema 3F was detected by immunostaining
using specific antibodies and FITC-conjugated secondary antibodies. Species and/or isotype-matched antibodies were used as negative controls. Following
labeling, cells were subjected to flow cytometry analysis. (c) Measurement of MM170 or A375 cell proliferation by 3H-thymidine DNA incorporation following
the addition of increasing concentrations of exogenous Sema 3F-AP. (d) Cells were transfected with soluble AP or Sema 3F-AP expression vector. Their
proliferation status, upon protein secretion, was evaluated after 2 days of recovery, as in (c). Before the addition of 3H-thymidine, the amount of secreted protein
was evaluated by measurement of the AP activity present in the transfected cell culture medium, and corresponded to a concentration of 25 nM in the
representative experiment shown in (d).
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TO THE EDITOR
While skin color is the most notable
difference among ethnic skins, many
other differences exist in the structure
and function of ethnic skins. Unfortu-
nately, the current knowledge of phy-
siological and pathological properties
of the skin is based mainly on Cauca-
sian skin studies (reviewed in Taylor,
2002). Elucidating differences among
ethnic skins is not only of great biolo-
gical importance, but also of great
interest in skin care improvement.
Keratinocytes play an important role
in skin physiology, affecting skin barrier
function, immune responses and
wound-healing processes (Williams
and Kupper, 1996). Earlier studies
documented the role of the keratinocyte
receptor PAR-2 in the regulation of skin
pigmentation (Seiberg et al., 2000a, b;
Paine et al., 2001), and the differential
expression of the PAR-2 pathway in
keratinocytes of different ethnic origins
(Babiarz-Magee et al., 2004). In order
to identify other differences in kerati-
nocytes’ expression profiles, we per-
formed DNA chip analysis of
keratinocytes obtained from different
skin types (four individuals of either
lightly (LK) or darkly (DK) pigmented
skins) (Cascade Biologics, Portland,
OR). When evaluating expression levels
of cathepsins (chip results, Table S1),
only cathepsin L2 (CTSL2) was found to
be differentially expressed in relation to
pigmentary skin backgrounds, and was
about 7.5-folds higher in keratinocytes
from lightly pigmented, relative to
darkly pigmented skins (Table S1).
CTSL2 is a lysosomal cysteine protease
(Adachi et al., 1998; Santamaria et al.,
1998; Bromme et al., 1999). It is
expressed in primary keratinocytes,
melanocytes, and HaCaT keratinocytes
(Figure 1a), but not in primary fibro-
blasts (Figure 1b). The differential ex-
pression of CTSL2 mRNA in
keratinocytes (but not of other cathe-
psins and of cystatins, the natural
inhibitors of cathepsins) was confirmed
by reverse transcriptase (RT)-PCR
(Figure 1c; Table S2 in Supplementary
material for primers). Interestingly,
melanocytes from different ethnic
origins expressed the same levels of
CTSL2 mRNA (Figure 1d).
Western blot analysis of keratino-
cytes using polyclonal antibodies
specific to CTSL2 (Figure S1) showed
that keratinocytes derived from lightly
pigmented skins (LK) have about
3.5-fold increase in CTSL2 protein
levels (normalized by b-actin) relative
to those of darkly pigmented skins (DK)
(Figure 2a). In addition, CTSL2 protein
levels in human skins with different
levels of pigment deposition (as shown
by Fontana–Mason staining, Figure 2b
and c) were analyzed by immunohisto-
chemistry staining. In agreement
with the CTSL2 mRNA levels in ethnic
skins, CTSL2 protein levels were
found to be higher in lighter skins, and
strongly reduced in darker skins
(Figure 2d and e).
To date, there are no specific in-
hibitors to CTSL2; therefore, we could
not directly measure CTSL2 activity in
keratinocyte’s derived from skins of
different colors. The total enzymatic
activity of cathepsins was measured
using substrate Z-Phe-Arg-AMC
(Bachem, Torrance, CA). Substrate
hydrolysis catalyzed by cathepsins
was monitored by fluorescent emission
(excitation at 360 nm and emission at
465 nm). Cell lysate of keratinocytes
from lightly pigmented skins showed
1.570.16-fold higher cathepsin activity
than keratinocytes derived from darker
skins (data were pooled from threeAbbreviations: CTSL2, cathepsin L2; RT, reverse transcriptase
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